Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling

Expert Review of Molecular Diagnostics

Volumn 2, Issue 6, 2002, Pages 565-575

  Minamoto, Toshinari ^a   Ougolkov, Andrei V ^a   Mai, Masayoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

catenin; Cancer; Colon and rectum; Diagnosis; K ras; Lung; Oncogene; Pancreas

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR PROTEIN;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CELL ADHESION; CELL TRANSFORMATION; COLON CANCER; GENE MUTATION; HUMAN; LUNG CANCER; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANIMAL; COLORECTAL TUMOR; EXPERIMENTAL NEOPLASM; FORECASTING; GENETICS; LUNG TUMOR; NEOPLASM; ONCOGENE RAS; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; RISK; TRANSGENIC ANIMAL;

ADENOCARCINOMA; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; FORECASTING; GENES, RAS; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ONCOGENES; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; RISK; TRANS-ACTIVATORS;

EID: 0036855318     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.6.565     Document Type: Review

References (75)

1. Ponder BAJ. Cancer genetics. Nature 411(6835), 336-341 (2001).
2. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 411(6835), 375-379 (2001).
3. Minamoto T, Ronai Z. Gene mutation as a target for early detection in cancer diagnosis. Crit. Rev. Oncol. Hematol. 40(3), 195-213 (2001).
4. Fearon ER. Human cancer syndromes: Clues to the origin and nature of cancer. Science 278(5340), 1043-1050 (1997).
5. Adjei AA. Blocking oncogenic ras signaling for cancer therapy. J. Natl. Cancer Inst. 93(14), 1062-1074 (2001).
6. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas and lung cancers - A review. Cancer Detect. Prev. 24(1), 1-12 (2000). Detailed data on the ability of molecular diagnosis of cancer patients and individuals at risk targeting the K-ras oncogene, which are obtained from the respective reports at its publication.
7. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 411(6835), 355-365 (2001).
8. Wong NA, Pignatelli M. β-catenin - A linchpin in colorectal carcinogenesis? Am. J. Pathol. 160(2), 389-401 (2002).
9. 2+ pathways. Oncogene 18(55), 7860-7872 (1999).
10. Taipale J, Beachy PA. The hedgehog and Wnt signalling pathways in cancer. Nature 411(6835), 349-354 (2001).
11. Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 82(8), 1419-1442 (1998).
12. Takayama T, Katsuki S, Takahashi Y et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 339(18), 1277-1284 (1998).
13. Takayama T, Ohi M, Hayashi T et al. Analysis of K-ras, APC and β-catenin in aberrant crypt foci in sporadic adenoma, cancer and familial adenomatous polyposis. Gastroenterology 121(3), 599-611 (2001).
14. Tada M, Ohashi M, Shiratori Y et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110(1), 227-231 (1996).
15. Miozzo M, Sozzi G, Musso K et al. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res. 56(10), 2285-2288 (1996).
16. Polakis P. The oncogenic activation of β-catenin. Curr. Opin. Genet. Dev. 9(1), 15-21 (1999).
17. -/- colon carcinoma. Science 275(5307), 1784-1787 (1997).
18. Morin PJ, Sparks AB, Korinek V et al. Activation of β-catenin - Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275(5307), 1787-1790 (1997).
19. Willert K, Nusse R. β-catenin a key mediator of Wnt signaling. Curr. Opin. Genet. Dev. 8(1), 95-102 (1998).
20. He TC, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science 281(5382), 1509-1512 (1998).
21. Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398(6726), 422-426 (1999).
22. Mann B, Gelos M, Siedow A et al. Target genes of β-catenin - T-cell-factor/lymphoid enhancer factor signaling in human colorectal carcinomas. Proc. Natl. Acad Sci. USA 96(4), 1603-1608 (1999).
23. Crawford HC, Fingleton BM, Rudolph-Owen LA et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 18(18), 2883-2891 (1999).
24. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. β-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 155(4), 1033-1038 (1999).
25. Van Aken E, DeWever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 439(6), 725-721 (2001)
26. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 278(5340), 1054-1059 (1997). Provides the fundamentals of molecular diagnosis and its impact on clinical practice.
27. Nakamura Y, Inazawa J. Genetic diagnosis of cancer. Int. J. Clin. Oncol. 3, 265-270 (1998).
28. Ponder B. Genetic testing for cancer risk. Science 278(5340), 1050-1054 (1997).
29. Perera FP. Environment and cancer: Who are susceptible? Science 278(5340), 1068-1073 (1997).
30. Minamoto T, Mai M, Ronai Z. Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis 20(4), 519-527 (1999).
31. Wu JS, Fazio VW. Colon cancer. Dis. Colon Rectum 43(11), 1473-1486 (2000).
32. Muto T, Kotake K, Koyama Y. Colorectal cancer statistics in Japan: Data from JSCCR registration, 1974-1993. Int. J. Clin. Oncol. 6(4), 171-176 (2001).
33. Rex DK, Rahmani EY, Haseman JH et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 112(1), 17-23 (1997).
34. Agrez MV, Coory M, Cockburn J. Population screening for colorectal carcinoma with fecal-occult blood testing: Are we sufficiently informed? Cancer 82(10), 1803-1807 (1998).
35. Burt RW. Colon cancer screening. Gastroenterology 119(3), 837-853 (2000).
36. Chung DC. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis. Gastroenterology 119(3), 854-865 (2000).
37. Brabletz T, Jung A, Hermann K, Günther K, Hohenberger W, Kirchner T. Nuclear overexpression of the oncoprotein β-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract. 194(10), 701-704 (1998).
38. Günther K, Brabletz T, Kraus C et al. Predictive value of nuclear β-catenin expression for the occurrence of distant metastases in rectal cancer. Dis. Colon Rectum 41(10), 1256-1261 (1998).
39. Hugh TJ, Dillon SA, O'Dowd G et al. β-catenin expression in primary and metastatic colorectal carcinoma. Int. J. Cancer 82(4), 504-511 (1999).
40. Maruyama K, Ochiai A, Akimoto S et al. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 59(4), 302-309 (2000).
41. Brabletz T, Jung A, Reu S et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 98(18), 10356-10361 (2001).
42. Ougolkov A, Yamashita K, Mai M, Minamoto T. Oncogenic β-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 122(1), 60-71 (2002). First report showing distinct patterns of oncogenic β-catenin activation in clinical colon cancer and their prevalence in and impact on molecular diagnosis of cancer patients.
43. Miyaki M, Iijima T, Kimura J et al. Frequent mutation of β-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res. 59(18), 4506-4509 (1999).
44. Mirabelli-Primdahl L, Gryfe R, Kim H et al. β-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 59(14), 3346-3351 (1999).
45. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 349(9050), 485-489 (1997).
46. Sener SF, Fremgen A, Menk HR, Winchester DP. Pancreatic cancer: A report of treatment and survival trends for 100313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. 189(1), 1-7 (1999).
47. Matsuno S, Egawa S, Shibuya K et al. Pancreatic cancer: Current status of treatment and survival of 16071 patients diagnosed from 1981-1996, using the Japanese National Pancreatic Cancer Database. Int. J. Clin. Oncol. 5(3), 153-157 (2000).
48. Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann F. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: A prospective controlled study. Lancet 356(9225), 190-193 (2000).
49. Gerdes B, Ramaswamy A, Simon B et al. Analysis of β-catenin gene mutations in pancreatic tumors. Digestion 60(6), 544-548 (1999).
50. Tanaka Y, Kato K, Notohara K et al. Frequent β-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res. 61(23), 8401-8404 (2001).
51. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J. Clin. 50(1), 7-33 (2000).
52. Mountain CF. Revisions in the international staging system for lung cancer. Chest 111 (6), 1710-1717 (1997).
53. Hirsch FR, Franklin WA, Gazder AF, Bunn PA Jr. Early detection in lung cancer: Clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 7(1), 5-22 (2001).
54. Shibanuma H, Hirano T, Tsuji K et al. Influence of E-cadherin dysfunction upon local invasion and metastasis in non-small cell lung cancer. Lung Cancer 22(2), 85-95 (1998).
55. Nawrocki B, Polette M, Van Hengel J, Tournier J-M, Van Roy F, Birembault P. Cytoplasmic redistribution of E-cadherin-catenin adhesion complex is associated with downregulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am. J. Pathol. 153(5),1521-1530 (1998).
56. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance. Clin. Cancer Res. 6(12), 4789-4796 (2000).
57. Hommura F, Furuuchi K, Yamazaki K et al. Increased expression of β-catenin predicts better prognosis in non-small cell lung cancer. Cancer 94(3), 752-758 (2002).
58. Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis and prognosis. Lung Cancer 36(2), 115-124 (2002).
59. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 18(1), 65-73 (1999).
60. Kopreski MS, Benko FA, Kwee C et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br. J. Cancer 76(10), 1293-1299 (1997).
61. Anker P, Lefort F, Vasioukhin V et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112(4), 1114-1120 (1997).
62. Hibi K, Robinson CR, Booker S et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res. 58(7), 1405-1407 (1998).
63. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: Identification of individuals harboring K-ras mutations with the use of plasma DNA. J. Natl. Cancer Inst. 92(11), 918-923 (2000) Original article that best demonstrates a paradigm of molecular diagnosis targeting K-ras oncogene through a well-organized, prospective study that subjects plasma DNA samples.
64. Mulcahy HE, Lyautey J, Ledderey C et al. A prospective study of K-ras mutation in the plasma of pancreatic cancer patients. Clin. Cancer Res. 4(2), 271-275 (1998).
65. Soussi T. p53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res. 60(7), 1777-1788 (2000).
66. Chen XQ, Stroun M, Magnenat JL et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med. 2(9), 1033-1035 (1996).
67. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med. 2(9), 1035-1037 (1996).
68. Goessl C, Heicappell R, Munker R et al. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res. 58(20), 4728-4732 (1998).
69. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59(1), 67-70 (1999).
70. Wong IH, Lo YM, Zhang J et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59(1), 71-73 (1999).
71. Silva J, Dominguez G, Villanueva M et al. Aberrant DNA methylation of the p16INK4a gene in plasma of breast cancer patients. Br. J. Cancer 80(8), 1262-1264 (1999).
72. Sanchez-Cespedes M, Esteller M, Wu L et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60(4), 892-895 (2000).
73. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61 (3), 900-902 (2001).
74. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 61(8), 3225-3229 (2001)
75. Tomberg SA. Screening for early detection of cancer-ethical aspects. Acta Oncol. 38(1), 77-81 (1999). Promising target for a new strategy of molecular diagnosis of human cancers. A series of promoter hypermethylation in a dozen of genes that play critical roles in tumor development and progression are analysed in DNA from over 600 tumor samples representing 15 major tumor types.